{
    "cancer_info": {
        "cancer_name": "B-Cell Lymphomas"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Excisional/incisional biopsy",
            "Core needle biopsy",
            "FNA with ancillary techniques (IHC, flow cytometry, FISH)",
            "Immunophenotyping (IHC/Flow): CD20, CD3, CD5, CD10, BCL2, BCL6, cyclin D1, MYC, Ki-67, IRF4/MUM1, CD30, CD15, EBER, HHV8",
            "FISH for MYC/BCL2/BCL6 rearrangements",
            "NGS lymphoma panel (CREBBP, EZH2, MAP2K1, TNFRSF14, STAT6, TP53)",
            "PET/CT or contrast-enhanced CT",
            "Bone marrow biopsy with flow cytometry",
            "LDH testing",
            "CBC with differential",
            "Comprehensive metabolic panel",
            "Hepatitis B/C serology",
            "HIV serology",
            "EBV PCR/EBER-ISH",
            "Lumbar puncture with CSF flow cytometry",
            "MUGA scan/echocardiogram",
            "Endoscopy (gastric MZL)",
            "β2-microglobulin testing",
            "Cryoglobulin testing",
            "Direct Coombs test",
            "Tumor lysis syndrome prophylaxis"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Follicular Lymphoma (Ann Arbor)",
            "risk_group": "Low tumor burden",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Asymptomatic",
                    "plan_name": "Observation",
                    "plan_details": "Active surveillance",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Standard"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Symptomatic",
                    "plan_name": "Rituximab monotherapy",
                    "plan_details": "4 weekly doses",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Follicular Lymphoma (Ann Arbor)",
            "risk_group": "High tumor burden",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "General",
                    "plan_name": "Bendamustine-rituximab",
                    "plan_details": "Bendamustine 90mg/m² + rituximab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "General",
                    "plan_name": "R-CHOP",
                    "plan_details": "Rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Maintenance",
                    "patient_subgroup": "Post-induction response",
                    "plan_name": "Rituximab maintenance",
                    "plan_details": "Every 8-12 weeks × 2 years",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Mantle Cell Lymphoma (Ann Arbor)",
            "risk_group": "TP53 mutated",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All patients",
                    "plan_name": "BOVen regimen",
                    "plan_details": "Zanubrutinib + obinutuzumab + venetoclax",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Suitable for aggressive therapy",
                    "plan_name": "TRIANGLE regimen",
                    "plan_details": "Alternating R-CHOP/ibrutinib/R-DHAP",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Other recommended"
                }
            ]
        },
        {
            "staging_criteria": "DLBCL (Ann Arbor)",
            "risk_group": "Early-stage (I-II non-bulky)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "General",
                    "plan_name": "R-CHOP ×3 + ISRT",
                    "plan_details": "3 cycles R-CHOP + involved-site radiation therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "DLBCL (Ann Arbor)",
            "risk_group": "Advanced-stage (III-IV/bulky)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "General",
                    "plan_name": "Pola-R-CHP",
                    "plan_details": "Polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Frail/elderly (≥80 years)",
                    "plan_name": "R-miniCHOP",
                    "plan_details": "Reduced-dose R-CHOP",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Burkitt Lymphoma",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "General",
                    "plan_name": "CODOX-M",
                    "plan_details": "Cyclophosphamide, vincristine, doxorubicin, methotrexate",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Marginal Zone Lymphoma (Gastric)",
            "risk_group": "Stage I-II H. pylori+",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "General",
                    "plan_name": "H. pylori eradication",
                    "plan_details": "Antibiotic therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "PTLD",
            "risk_group": "Monomorphic B-cell",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "General",
                    "plan_name": "RI + rituximab",
                    "plan_details": "Reduction of immunosuppression + rituximab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "BCL2 rearrangement (t(14;18)): Diagnostic hallmark for follicular lymphoma",
            "EZH2 mutations: Predict response to tazemetostat in relapsed/refractory FL",
            "TP53 mutations: Strongest adverse prognostic factor in MCL; requires targeted therapy",
            "MYC/BCL2/BCL6 rearrangements: Define high-grade B-cell lymphoma; require intensive therapy",
            "t(11;18) in gastric MZL: Predicts resistance to H. pylori eradication therapy",
            "CD30 positivity: Enables brentuximab vedotin use in CD30+ lymphomas",
            "9p24 alterations (PMBCL): Predict sensitivity to PD-1 inhibitors",
            "EBV positivity: Associated with aggressive disease in HIV-related lymphomas",
            "Ki-67 >30%: Adverse prognostic factor in MCL and transformed lymphomas"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：B细胞淋巴瘤.txt"
}